In conclusion, despite the limitations of this meta-analysis, our study still demonstrated that low/negative TYMS expression was significantly associated with higher response rate, longer median overall survival and longer progression free survival for advanced NSCLC patients receiving pemtrexed-containing chemotherapy. Here, TYMS is linked to non-small cell lung carcinoma.